The economics of treating chronic hepatitis B in Asia

Hepatology International

Volumn 2, Issue 3, 2008, Pages 284-295

  Dan, Yock Young ^a,b   Aung, Myat Oo ^c   Lim, Seng Gee ^a,b,c  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c AGENCY FOR SCIENCE   (Singapore)

Author keywords

Cost effectiveness analysis; Hepatitis B treatment

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE;

ASIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; RISK REDUCTION; SEROCONVERSION; VIRUS REPLICATION;

EID: 51049105788     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9049-2     Document Type: Review

References (44)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Lesmana LALN-Y, Mahachai V, Phiet PH, Suh DJ, Yao GB. Hepatitis B: overview of the burden of disease in the Asia-Pacific region. Liver Int 2006;26:3-10.
3. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211, v.
4. Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol 2001;16:301-8.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology (Baltimore, MD) 2007;45:507-39.
6. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
7. Holodniy M. HIV-1 load quantitation: A 17-year perspective. J Infect Dis 2006;194 Suppl 1:S38-44.
8. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
9. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.
10. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.
11. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology (Baltimore, MD) 1999;29:971-5.
12. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-38.
13. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003;6:9-17.
14. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (Baltimore, MD) 2005;42:1414-9.
15. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology (Baltimore, MD) 2006;44:1656-65.
16. Dan YY, Lim SG. Cost effectiveness of chronic Hepatitis B (Abstract). Hepatology 2006;44(S1):562A.
17. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002;17:153-64.
18. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
19. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: A cost-effectiveness analysis. Ann Intern Med 2005;142:821-31.
20. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. PharmacoEconomics 2007;25:963-77.
21. Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat 2007;14:75-88.
22. Veenstra DL, Sullivan SD, Dusheiko GM, et al. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. Eur J Gastroenterol Hepatol 2007;19:631-8.
23. Sullivan SD, Veenstra DL, Chen P-J, Chang T-T, Chuang W-L, Tsai C, et al. Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with HBe-antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol 2007;22:1494-9.
24. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-89.
25. Lai CLGE, Hsu CW. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine (Abstract). Hepatology (Baltimore, MD) 2006;44:222A.
26. Wong J, Stephen P. Cost-effectiveness of telbivudine versus lamivudine for chronic Hepatitis B (Abstract). J Hepatol 2007;46(S1):S199.
27. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998;13:716-7.
28. WHO. Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health: Executive Summary. World Health Organisation. 2001.
29. Bank W. GNI 2006 Atlas Method: World Development Indicators database. 2007.
30. Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004;38:S148-52.
31. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
32. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
33. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
34. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
35. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
37. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
38. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
39. Guan R, Lai CL, Liaw YF, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001;16 Suppl 1:A60 (Abstract).
40. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51.
41. Marcellin PCT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients in Study GS-98-437. 57th Annual Meeting of the American Association for the Study of Liver Disease. Boston, MA. 2006.
42. Chang TC, Kaymakoglu S. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901). 57th Annual Meeting of the American Association for the Study of Liver Disease. Boston, MA. 2006.
43. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology (Baltimore, MD) 1995;22:1863-73.
44. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation. Health Technol Assess (Winchester, England) 2006;10:iIi-iv, xi-xiv, 1-183.